Department of Anthropology, University of Nebraska-Lincoln, 839 Old Father Hall, Lincoln, NE 68588, United States of America.
Department of Administration of Justice, Penn State Greater Allegheny, 400 University Drive, McKeesport, PA 15216, United States of America.
J Subst Abuse Treat. 2021 Aug;127:108347. doi: 10.1016/j.jsat.2021.108347. Epub 2021 Mar 3.
Research has shown medication for opioid use disorder (MOUD) to have positive effects, including reducing HIV and HCV transmission, but important barriers to access remain among people who inject drugs (PWID). Barriers include lack of social and familial support, bureaucracy, distance to treatment, poverty, and homelessness. However, we know little about how these barriers interact with each other to shape PWID's drug treatment access and retention.
We used qualitative methods with a dataset from a study conducted during 2019 with 31 active PWID residing in rural Puerto Rico. The study gathered ethnographic data and narratives about treatment trajectories to document the lived experiences of PWID as they moved in and out of treatment.
Participants were at least 18 years old; 87.7% were male, the mean age was 44.1 years, and the mean age at first injection was 22 years. Participants identified homelessness, lack of proper ID or other identifying documents, and previous negative experiences with MOUD as the main barriers to treatment entry and retention. In addition, PWID's belief that MOUD simply substitutes an illegal drug for a legal one, while furthering drug dependence by chronically subjecting patients to treatment, constitutes an additional barrier to entry. Findings from this study demonstrate that MOUD barriers to access and retention compound and are severely affected by poverty and other forms of vulnerability among PWID in rural Puerto Rico.
Policies to increase access and retention should consider barriers not in isolation but as an assemblage of many factors.
研究表明,治疗阿片类药物使用障碍(MOUD)药物具有积极作用,包括降低 HIV 和 HCV 的传播,但注射吸毒者(PWID)获得治疗的重要障碍仍然存在。这些障碍包括缺乏社会和家庭支持、官僚主义、治疗距离、贫困和无家可归。然而,我们对于这些障碍如何相互作用,从而影响 PWID 的药物治疗获得和保留知之甚少。
我们使用定性方法,对 2019 年在波多黎各农村地区进行的一项研究中的数据集进行了分析。该研究收集了关于治疗轨迹的民族志数据和叙述,以记录 PWID 在治疗期间进出治疗的真实经历。
参与者年龄至少为 18 岁;87.7%为男性,平均年龄为 44.1 岁,首次注射年龄为 22 岁。参与者认为无家可归、缺乏适当的 ID 或其他身份证明文件,以及之前对 MOUD 的负面经历是进入和维持治疗的主要障碍。此外,PWID 认为 MOUD 只是用合法药物替代非法药物,通过长期使患者接受治疗来进一步导致药物依赖,这也是进入治疗的另一个障碍。这项研究的结果表明,MOUD 在获得和维持治疗方面的障碍相互叠加,并严重受到波多黎各农村地区 PWID 中的贫困和其他形式脆弱性的影响。
增加获得和维持治疗的政策应考虑到障碍不是孤立的,而是许多因素的组合。